HomeCompareNCRBF vs JNJ

NCRBF vs JNJ: Dividend Comparison 2026

NCRBF yields 3.81% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.7K in total portfolio value· pulled ahead in Year 9
10 years
NCRBF
NCRBF
● Live price
3.81%
Share price
$31.57
Annual div
$1.20
5Y div CAGR
-0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$476.50
Full NCRBF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NCRBF vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNCRBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NCRBF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NCRBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NCRBF
Annual income on $10K today (after 15% tax)
$324.14/yr
After 10yr DRIP, annual income (after tax)
$405.03/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,580.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NCRBF + JNJ for your $10,000?

NCRBF: 50%JNJ: 50%
100% JNJ50/50100% NCRBF
Portfolio after 10yr
$27.9K
Annual income
$2,582.95/yr
Blended yield
9.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NCRBF
No analyst data
Altman Z
3.3
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NCRBF buys
0
JNJ buys
0
No recent congressional trades found for NCRBF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNCRBFJNJ
Forward yield3.81%2.13%
Annual dividend / share$1.20$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.2%28%
Portfolio after 10y$25.6K$30.3K
Annual income after 10y$476.50$4,689.40
Total dividends collected$4.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NCRBF vs JNJ ($10,000, DRIP)

YearNCRBF PortfolioNCRBF Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,081$380.58$10,592$272.30+$489.00NCRBF
2$12,250$393.33$11,289$357.73+$961.00NCRBF
3$13,513$405.56$12,123$472.89+$1.4KNCRBF
4$14,876$417.28$13,141$629.86+$1.7KNCRBF
5$16,346$428.46$14,408$846.81+$1.9KNCRBF
6$17,929$439.12$16,021$1,151.60+$1.9KNCRBF
7$19,633$449.24$18,122$1,588.22+$1.5KNCRBF
8$21,466$458.84$20,930$2,228.20+$536.00NCRBF
9← crossover$23,437$467.92$24,792$3,191.91$1.4KJNJ
10$25,554$476.50$30,274$4,689.40$4.7KJNJ

NCRBF vs JNJ: Complete Analysis 2026

NCRBFStock

Nippon Carbon Co., Ltd. engages in the manufacture and sale of carbon products in Japan. It offers carbon fiber products, including molded heat insulating materials for high temperature furnaces; CARBORON, a soft felt used in a range of heat insulators for high temperature furnaces; C/C Composite, a lightweight carbon material used in heat resistant composite structural members, high temperature furnace materials, trays, jigs, etc.; and CARBEST, a carbon fiber packing material. The company also provides specialty carbon products, such as isotropic graphite, a graphite material; high purity treatment graphite used for manufacturing device components for silicon semiconductors, compound semiconductors, and optical fibers; carbon products for mechanical components that are used in various fields of science, including electronics, machinery, and the metallurgy industry; VESCOAT, a silicon carbide coated product used for silicon semiconductor, LED, and manufacturing device components for optical fibers; and SC CARBON sliding composites. In addition, it offers artificial graphite electrodes for use in high-power electric arc furnaces; silicon carbide continuous fibers, such as Nicalon, Hi-Nicalon, and Hi-Nicalon TypeS for use as reinforcement fibers in ceramic composite materials, plastic composite materials, and others; and lithium ion secondary batteries used for cellular and smart phones, NBPC, tablet terminals, power tools, hybrid automobiles, and electric automobiles. Further, the company provides impervious graphite RESBON, a corrosion-resistant material; NICABEADS, which are surface-coated micro bead-shape materials; and NICAFILM, a flexible graphite sheet made from natural graphite. The company was incorporated in 1915 and is headquartered in Tokyo, Japan.

Full NCRBF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NCRBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NCRBF vs SCHDNCRBF vs JEPINCRBF vs ONCRBF vs KONCRBF vs MAINNCRBF vs ABBVNCRBF vs MRKNCRBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.